LOGIN  |  REGISTER
Chimerix

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

February 20, 2024 | Last Trade: US$19.34 0.86 -4.26

DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary, Florida, which offers advanced patient access solutions across the United States, including ambient and cold-chain distribution capabilities and expertise.

Licensed in all 50 states and U.S. territories, FortreaRx delivers flexible, scalable solutions that meet the specific needs of its customers while providing medications to patients who may otherwise not have access to them. Non-commercial specialty pharmacies, like FortreaRx, provide these solutions on behalf of their pharmaceutical manufacturer customers and are uniquely positioned to serve as a bridge between pharmaceutical manufacturers and patients who meet the manufacturer requirements for prescription assistance.

Since FortreaRx’s inception in late 2008, Fortrea has pioneered non-commercial specialty pharmacy services, focusing exclusively on the distribution of free-goods products as an integrated component of pharmaceutical manufacturer-sponsored patient assistance programs (PAP) designed to expand access to therapy for qualified patients with no health insurance or those who are underinsured. The FortreaRx 40,000-square-foot facility doubles its operational space and bolsters its capabilities, delivering:

  • 1,800 square feet of ambient storage
  • 6,000+ square feet of cold chain storage with more than 85 percent of prescriptions filled by FortreaRx requiring this unique handling
  • Greater processing and fulfillment space for up to 18,000 prescriptions daily
  • Enhanced shipping solutions with options for overnight, expedited and 2-day deliveries

"Fortrea’s well-established patient services offerings, combined with the expanded capabilities of FortreaRx, deliver an end-to-end approach, from early clinical stages to post-market delivery, ensuring a comprehensive and personalized experience for patients," said Bill Nolan, vice president and global head of Patient Access at Fortrea. "From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives."

FortreaRx’s call center hub of case managers seamlessly manages patient inquiries, counseling and data verification of prescriptions. Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.

FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programs typically resulting in significant yearly savings for patients.

For more information about FortreaRx and its services, please visit Fortrea.com.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, This email address is being protected from spambots. You need JavaScript enabled to view it.
Fortrea Media: Kate Dillon – 646-818-9115, This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB